$VPRO .0043 Going, Ran Trips to .20+ Huge DD Multi Dollar Value, New Management, New Website & Huge Products
Partners are Big
BRI Biopharmaceutical Research http://www.bripharm.com
CoreRX Pharma
http://www.corerxpharma.com
Spectrum Pharmaceutical Inc. $7.00+ on Nasdaq
http://www.sppirx.com
Oncobiologics
http://www.oncobiologics.com
Alpha Biologics
http://www.alphabiologics.com
Huge Documents Involving Gilead, Celgene, Amgen, Biogene Idec and So Many Top Pharmaceuticals...VIROPRO is a Steal considering the Competitor's Value.... 73 Page Pharmaceutical & Biotechnology 2014 Outlook >> https://www.google.ca/url?sa=t&source=web...7CmJfnK8QA
New Website >> http://www.viropro.net
Active SOS >> https://nvsos.gov/sosentitysearch/CorpDetails...amp;nt7=0j
Outstanding Shares 916,000,000
Float 39,000,000
Insiders Holdings 48,000,000
Institutional Holdings 631,000,000
INSTITUTIONAL HOLDINGS
Spring Hill Bioventures Sdn Bhd
340,000,000
THG Capital Sdn Bhd
184,000,000
Intas Biopharmaceuticals Ltd.
106,916,666
Employees
The Company has 34 employees. Two of the employees are Viropro’s senior executive officers and seven are employees of BPD. Under Alpha Biologics, there are 20 employees in Penang, Malaysia and 5 in Cambridge, UK.
Portfolio Valuation
Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products.
Projected Revenues
The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60–$150 million for Viropro within 10 years. The partnership is planning to launch its first product by late 2014.
The products include biosimilar version of Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (trastuzumab), Humira (adalimumab), Rituxan (rituximab) and a non-disclosed biological used for cancer and immune-disease indications.
New Management with Absolutely Huge Portfolios as of 2014
http://www.viropro.net/leadership-team/
The Board appointed Dr. Joseph J. Vallner as Acting President and Bruce A. Cohen as Chairman of the Board. Since 2009 Dr. Vallner has served as a consultant primarily to small pharmas/biotech companies and was previously President of ORUUS Pharma, a cancer drug delivery company, Lumera Corp., a company that developed products for electro-optics applications, which was a publicly traded company on NASDAQ during the time Dr. Vallner was its President and CEO, and President and CEO of Capnia, a company that developed nasal delivery of therapeutic gas for migraine and other inflammation disorders. Dr. Vallner received his BS degree in Pharmacy, his MS degree in
hysical Chemistry and his PhD in Pharmaceutics (Biochemistry minor) from the University of Wisconsin. The Board is negotiating an employment agreement with Dr. Vallner.
Bruce A. Cohen has served as founding President and CEO of several biotech companies and assisted them with financings, including Vitapath Genetics, Inc. from 2008-2012, a personalized genetics company, Cellerant Therapeutics, Inc., from 2002-2007, a stem cell therapy company, and Acacia Biosciences, Inc. from 1997-2000, a bioinformatics-based functional genomics discovery company. Mr. Cohen was CFO of GeneSoft Pharmaceuticals from 2000-2001 and Vice President at SEQUUS Pharmaceuticals, Inc. from 1995-1997, a pharma company involved with liposome-based oncology and anti-infective drugs. Prior to these executive roles, Mr. Cohen was the President and COO of ViTel International and a management consultant with Monitor Company. Mr. Cohen has an MBA with distinction from Harvard Business School, and a BA and MA from Tufts University.
Viropro, Inc. and Oncobiologics, Inc. have signed a biosimilar collaboration agreement, under which Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging markets (excluding China).
Viropro will have commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Alpha Biologics biomanufacturing subsidiary in Penang, Malaysia.
The biosimilars are generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux, and one other non-disclosed biotherapeutic. The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue rate of $60–$150 million in 10 years. The partnership plans to launch its first product by late 2014.
Competitors Capitalization
Lonza Group AG (SWX:LONN)
$3.2 billion
Pharmaceutical Product Development, Inc. (Nasadaq PDI)
$3.8 billion
Cambrex Corporation (NYSE:CBM)
$210 million
Bioanalytical Systems, Inc. (Nasdaq:BASI)
$7.1 million
Viropro,Inc. (PINK :VPRO)
$2 million
Partners are Big
BRI Biopharmaceutical Research http://www.bripharm.com
CoreRX Pharma
http://www.corerxpharma.com
Spectrum Pharmaceutical Inc. $7.00+ on Nasdaq
http://www.sppirx.com
Oncobiologics
http://www.oncobiologics.com
Alpha Biologics
http://www.alphabiologics.com
Huge Documents Involving Gilead, Celgene, Amgen, Biogene Idec and So Many Top Pharmaceuticals...VIROPRO is a Steal considering the Competitor's Value.... 73 Page Pharmaceutical & Biotechnology 2014 Outlook >> https://www.google.ca/url?sa=t&source=web...7CmJfnK8QA
New Website >> http://www.viropro.net
Active SOS >> https://nvsos.gov/sosentitysearch/CorpDetails...amp;nt7=0j
Outstanding Shares 916,000,000
Float 39,000,000
Insiders Holdings 48,000,000
Institutional Holdings 631,000,000
INSTITUTIONAL HOLDINGS
Spring Hill Bioventures Sdn Bhd
340,000,000
THG Capital Sdn Bhd
184,000,000
Intas Biopharmaceuticals Ltd.
106,916,666
Employees
The Company has 34 employees. Two of the employees are Viropro’s senior executive officers and seven are employees of BPD. Under Alpha Biologics, there are 20 employees in Penang, Malaysia and 5 in Cambridge, UK.
Portfolio Valuation
Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products.
Projected Revenues
The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60–$150 million for Viropro within 10 years. The partnership is planning to launch its first product by late 2014.
The products include biosimilar version of Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (trastuzumab), Humira (adalimumab), Rituxan (rituximab) and a non-disclosed biological used for cancer and immune-disease indications.
New Management with Absolutely Huge Portfolios as of 2014
http://www.viropro.net/leadership-team/
The Board appointed Dr. Joseph J. Vallner as Acting President and Bruce A. Cohen as Chairman of the Board. Since 2009 Dr. Vallner has served as a consultant primarily to small pharmas/biotech companies and was previously President of ORUUS Pharma, a cancer drug delivery company, Lumera Corp., a company that developed products for electro-optics applications, which was a publicly traded company on NASDAQ during the time Dr. Vallner was its President and CEO, and President and CEO of Capnia, a company that developed nasal delivery of therapeutic gas for migraine and other inflammation disorders. Dr. Vallner received his BS degree in Pharmacy, his MS degree in
hysical Chemistry and his PhD in Pharmaceutics (Biochemistry minor) from the University of Wisconsin. The Board is negotiating an employment agreement with Dr. Vallner. Bruce A. Cohen has served as founding President and CEO of several biotech companies and assisted them with financings, including Vitapath Genetics, Inc. from 2008-2012, a personalized genetics company, Cellerant Therapeutics, Inc., from 2002-2007, a stem cell therapy company, and Acacia Biosciences, Inc. from 1997-2000, a bioinformatics-based functional genomics discovery company. Mr. Cohen was CFO of GeneSoft Pharmaceuticals from 2000-2001 and Vice President at SEQUUS Pharmaceuticals, Inc. from 1995-1997, a pharma company involved with liposome-based oncology and anti-infective drugs. Prior to these executive roles, Mr. Cohen was the President and COO of ViTel International and a management consultant with Monitor Company. Mr. Cohen has an MBA with distinction from Harvard Business School, and a BA and MA from Tufts University.
Viropro, Inc. and Oncobiologics, Inc. have signed a biosimilar collaboration agreement, under which Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging markets (excluding China).
Viropro will have commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Alpha Biologics biomanufacturing subsidiary in Penang, Malaysia.
The biosimilars are generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux, and one other non-disclosed biotherapeutic. The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue rate of $60–$150 million in 10 years. The partnership plans to launch its first product by late 2014.
Competitors Capitalization
Lonza Group AG (SWX:LONN)
$3.2 billion
Pharmaceutical Product Development, Inc. (Nasadaq
PDI) $3.8 billion
Cambrex Corporation (NYSE:CBM)
$210 million
Bioanalytical Systems, Inc. (Nasdaq:BASI)
$7.1 million
Viropro,Inc. (PINK :VPRO)
$2 million
